[{"id":"4efe55f5-ab89-4aee-9412-8795b2078c91","acronym":"","url":"https://clinicaltrials.gov/study/NCT05500027","created_at":"2022-11-08T19:21:37.300Z","updated_at":"2024-07-02T16:36:05.597Z","phase":"","brief_title":"sCD8, as a Novel Biomarker for Pancreatic Cancer","source_id_and_acronym":"NCT05500027","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" TGFB1 • CD58 • CA 19-9","pipe":"","alterations":" ","tags":["TGFB1 • CD58 • CA 19-9"],"overall_status":"Recruiting","enrollment":" Enrollment 2000","initiation":"Initiation: 05/01/2021","start_date":" 05/01/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2022-08-12"},{"id":"cca55acd-fe7d-4fd1-a867-4d67afcb638c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02179515","created_at":"2021-01-18T10:09:59.893Z","updated_at":"2024-07-02T16:36:35.567Z","phase":"Phase 1","brief_title":"Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)","source_id_and_acronym":"NCT02179515","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • IFNG • TNFA • IL2 • ICAM1 • IL10 • CD27 • LAMP1 • CD58 • CD40LG • IL4","pipe":" | ","alterations":" ER positive • EGFR mutation • CD8 expression","tags":["CD8 • IFNG • TNFA • IL2 • ICAM1 • IL10 • CD27 • LAMP1 • CD58 • CD40LG • IL4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • EGFR mutation • CD8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BN-Brachyury"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 06/28/2014","start_date":" 06/28/2014","primary_txt":" Primary completion: 04/06/2017","primary_completion_date":" 04/06/2017","study_txt":" Completion: 02/28/2018","study_completion_date":" 02/28/2018","last_update_posted":"2021-01-26"}]